Abstract：Objective：To observe the curative effect of Shenshuaining combined with Sacubitril Valsartan Sodium on chronic renal insufficiency （CRI）. Methods： A total of 100 cases of CRI patients treated at Shangyu People's Hospital of Shaoxing from January 2022 to January 2024 were selected and divided into the observation group （52 cases） and the control group （48 cases） based on different treatment regimens. The control group was treated with Sacubitril Valsartan Sodium， and the observation group was additionally treated with Shenshuaining combined with Sacubitril Valsartan Sodium. Clinical effects and the incidence of adverse reactions were compared between the two groups. Changes in traditional Chinese medicine syndrome scores，kidney function-related indicators [serum creatinine （SCr）， blood urea nitrogen （BUN）， serum uric acid （UA）， serum cystatin C （Cys C）， serum albumin （Alb）， hemoglobin （Hb）， estimated glomerular filtration rate （e-GFR）， 24-hour urinary protein quantification]， and inflammation indicators [interleukin-6 （IL-6）， interleukin-8 （IL-8）， C-reactive protein （CRP）] in the two groups were compared before and after treatment. Results： The total effective rate of clinical effect in the observation group was 92.31% （48/52），compared to 77.08% （37/48） in the control group，with a significant difference between the two groups （P＜0.05）. After treatment，traditional Chinese medicine syndrome scores for poor appetite，lumbar and knee soreness， fatigue， and abdominal distension in the two groups were decreased， with the observation group showing lower scores than the control group （P＜0.05）. After treatment，the levels of SCr，BUN，UA，Cys C，and 24-hour urinary protein quantification in the two groups were reduced （P＜0.05），and the levels of Alb，Hb，and e-GFR were increased when compared with those before treatment （P＜0.05）；the observation group had lower levels of SCr，BUN， UA，Cys C，and 24-hour urinary protein quantification and higher levels of Alb，Hb，and e-GFR compared to the control group （P＜0.05）. After treatment，the levels of IL-6，IL-8，and CRP in the two groups were reduced when compared with those before treatment （P＜0.05）， with the observation group showing lower levels than the control group （P＜0.05）. There was no significant difference in the incidence of adverse reactions between the two groups （P＞ 0.05）. Conclusion：Shenshuaining combined with Sacubitril Valsartan Sodium can improve kidney function，alleviate clinical symptoms，reduce inflammation responeses，and enhance clinical efficacy in the treatment of CRI.